Fig. 2From: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis2A, PFS in patients treated with pembrolizumab plus chemotherapy and pembrolizumab monotherapy; 2B, OS in patients treated with pembrolizumab plus chemotherapy and pembrolizumab monotherapyBack to article page